Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

GNG Systematic Research | February 2026 Picture a 177-year-old company that just printed $62.6 billion in annual revenue, beat quarterly earnings estimates by 14%, and pays you 6.3% to hold it. Now picture that same company trading 55% below its 2021 peak, with a consensus rating of "Hold" and an average analyst target barely above the current price. That gap between what Pfizer earns and what the market believes it deserves is the entire thesis in one sentence. At $27.61, the stock sits at 9.6x forward earnings and just pennies below its 52-week high of $27.69. The Vulcan screening system flags PFE as a conditional buy for income and value accounts, not a back-up-the-truck conviction position. You are buying a large-cap pharma franchise where the math works if things stay roughly the same, and the upside comes free if the pipeline delivers. Staged sizing at 0.5% to 1.0% of portfolio, with clear invalidation triggers. Patience over panic. The Business Beneath the Headlines Pfizer is one of the world's largest pharmaceutical companies, generating roughly $60 billion in annual revenue from prescription drugs and vaccines, with international sales representing about 40% of the total. The blockbuster roster includes cardiovascular drug Vyndaqel, oncology asset Padcev (from the $43 billion Seagen acquisition), blood thinner Eliquis, migraine treatment Nurtec, and the Prevnar vaccine family. Here is the number Wall Street keeps overlooking: strip out the COVID products, Comirnaty and Paxlovid, and the underlying portfolio grew 6% operationally in 2025. Full-year adjusted EPS came in at $3.22, up from $3.11 the prior year. Q4 adjusted EPS of $0.66 beat the $0.58 consensus by 14%. Recently launched and acquired products delivered $10.2 billion in 2025 revenue, growing approximately 14% operationally. This is not a business in decline. This is a business with a COVID-shaped hole in the revenue line that the market is treating like a structural flaw. Profitability metrics confirm the franchise quality. Gross margins expanded to 76% on an adjusted basis in 2025. Operating margin sits at 24.6%, net margin at 15.7%. ROIC of 8.2% exceeds the 6.3% weighted average cost of capital, producing a positive spread of roughly 190 basis points. Not elite by software standards, but defensible and sustainable for mature pharma. Our Vulcan system scores PFE at Quality 85/100 (2nd decile in Healthcare), Value 81/100, and Sentiment 80/100. Growth registers just 51/100, which is honest: this is not a growth story yet. Piotroski F-Score of 7 indicates solid financial health. Beneish M-Score at negative 2.38 shows no earnings manipulation flags. Altman Z-Score of 2.2 sits in the grey zone, typical for large-cap pharma carrying acquisition-related debt. The Obesity Pipeline Nobody Is Pricing Here is where the narrative gets interesting. Pfizer spent $10 billion acquiring Metsera, an obesity biotech, and the early data deserves more attention than it is getting. Phase 2b results from the VESPER-3 trial showed PF'3944, an ultra-long-acting GLP-1 receptor agonist, delivered up to 12.3% weight loss in patients without diabetes. The differentiator is the dosing profile: monthly maintenance injections versus the weekly regimens required by Novo Nordisk and Eli Lilly's competing products. Pfizer has mapped out ten Phase 3 obesity trials for 2026 alone, including the VESPER-4 trial for weekly dosing in obesity, VESPER-5 for patients with type 2 diabetes, and VESPER-6 for monthly dosing. If even a fraction of those read out favorably, the market's perception shifts from "post-COVID melter" to "late entrant with differentiated GLP-1 franchise." At 9.6x forward earnings, none of that optionality is reflected in the price. The Seagen portfolio is also progressing ahead of management's expectations despite a $4.4 billion Q4 impairment charge tied to specific asset revaluations (not portfolio-wide weakness). Padcev continues expanding in earlier